

With Ferinject[®]



Their world awaits

Meaningful benefits for your IBD patients



• Significant higher Hb response or normalisation vs standard treatment¹

• Significant improvement in their overall quality of life¹

- improvement in physical health
- improvement in mental health

• Improved compliance vs standard treatment^{1,2}

How does Ferinject[®] ***make a difference?***

Proven data for efficacy and tolerability²⁻²⁷

- 26 interventional studies
- >2,200,000 patient years*

Rapid repletion of iron stores^{2,5}

- More efficient repletion than with oral iron

Lasting impact^{17,21}

- Postponed recurrence of IDA as a comorbidity

High iron availability in target tissues³

- Utilisation rate of up to 99%


Controlled release of iron³

- Stable carbohydrate complex that provides controlled release of iron

Simple, fast and convenient dosing³

- Single dose up to 1000 mg iron
- 1000 mg iron in 15 minutes
- As infusion or injection

* Data on file: covers the period from international birth date to 31 December 2014.



ferinject[®]

ferric carboxymaltose

References: **1.** Evstatiev R et al. Gastroenterology. 2011; 141(3): 846–53.e1–2. **2.** Kulnigg S et al. Am J Gastroenterol. 2008; 103(5): 1182–92. **3.** Ferinject[®] Summary of Product Characteristics. **4.** Onken JR et al. Transfusion. 2014; 54(2): 306–15. **5.** Qunibi WY et al. Nephrol Dial Transplant. 2011; 26(5): 1599–607. **6.** Huch R and Schaefer R. Iron deficiency and iron deficiency anaemia. Thieme Medical Publishers; 2006. **7.** Crichton R et al. Iron Therapy With Special Emphasis on Intravenous Administration. 4th Edition. London, Boston: International Medical Publishers; 2008. **8.** Favrat B et al. PLoS One. 2014; 9(4): e94217. doi: 10.1371/journal.pone.0094217. eCollection 2014. **9.** Breymann C et al. Int J Gynaecol Obstet. 2008; 101(1): 67–73. **10.** Van Wyck DB et al. Obstet Gynecol. 2007; 110(2 Pt 1): 267–78. **11.** Van Wyck DB et al. Transfusion. 2009; 49(12): 2719–28. **12.** Seid MH et al. Am J Obstet Gynecol. 2008; 199(4): 435.e1–7. **13.** Beshara S et al. Br J Haematol. 2003; 120(5): 853–9. **14.** Covic A and Mircescu G. Nephrol Dial Transplant. 2010; 25(8): 2722–30. **15.** Bailie GR et al. Hemodial Int. 2010; 14(1): 47–54. **16.** Charytan C et al. Nephrol Dial Transplant. 2013; 28(4): 953–64. **17.** Onken JE et al. Nephrol Dial Transplant. 2014; 29(4): 833–42. **18.** Macdougall IC et al. Nephrol Dial Transplant. 2014. pii: gfu201. [Epub ahead of print]. **19.** Anker SD et al. NEJM. 2009; 361(25): 2436–48. **20.** Geisser P and Rumyantsev V. Arzneimittelforschung. 2010; 60(6a): 373–85. **21.** Evstatiev R et al. Clin Gastroenterol Hepatol. 2013; 11(3): 269–77. **22.** Kulnigg-Dabsch S et al. Inflamm Bowel Dis. 2013; 19(8): 1609–16. **23.** Allen RP et al. Sleep Med. 2011; 12(9): 906–13. **24.** Geisser P et al. Arzneimittelforschung. 2010; 60(6a): 362–72. **25.** Barish CF et al. Anemia. 2012; 2012: 172104. Epub 2012 Sep 10. **26.** Hussain I et al. Anemia. 2013; 2013: 169107. Epub 2013 Aug 29. **27.** Ponikowski P et al. Eur Heart J. 2014 Aug 31. pii: ehu385. [Epub ahead of print].